Table 3.

Estimated prevalence of post-MI patients eligible to PCSK9 inhibitors according to the EAS/ESC and AIFA criteria.

EAS/ESC criteria (n = 2977)	N	%
Statin and/or ezetimibe† + noDM + LDL-C >140 mg/dl	130	4,37
Statins and/or ezetimibe† + DM + LDL-C >100 mg/dl	163	5.48
AIFA criteria (n = 2029)
High intensity statins and ezetimbe‡ + age ≤80 yrs + eCrCl ≥ 30 ml/min + LDL-C >100 mg/dl	450	22.2

DM, diabetes mellitus; eCrCl, estimated creatinine clearance, LDL-C, low density lipoprotein cholesterol.

^†These groups included patients receiving any statins at any dosage. Monoterapy with ezetimibe has been taken as a proxy of statin intolerance.

^‡High intensity statins have been considered atorvastatin 40–80 mg /day or rosuvastatin 20–40 mg/day. Monoterapy with ezetimibe has been taken as a proxy of statin intolerance.